Published in J Exp Med on March 01, 1989
Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A (1994) 3.77
In vivo induction of anergy in peripheral V beta 8+ T cells by staphylococcal enterotoxin B. J Exp Med (1990) 2.69
Successful T cell priming in B cell-deficient mice. J Exp Med (1995) 2.52
A fail-safe mechanism for maintaining self-tolerance. J Exp Med (1992) 2.10
CD45-null transgenic mice reveal a positive regulatory role for CD45 in early thymocyte development, in the selection of CD4+CD8+ thymocytes, and B cell maturation. J Exp Med (1996) 1.83
Long-lasting CD8 T cell memory in the absence of CD4 T cells or B cells. J Exp Med (1996) 1.50
Cross-species bone marrow transplantation: evidence for tolerance induction, stem cell engraftment, and maturation of T lymphocytes in a xenogeneic stromal environment (rat----mouse). J Exp Med (1991) 1.46
Conditions that induce tolerance in mature CD4+ T cells. J Exp Med (1997) 1.45
Medawar's legacy to cellular immunology and clinical transplantation: a commentary on Billingham, Brent and Medawar (1956) 'Quantitative studies on tissue transplantation immunity. III. Actively acquired tolerance'. Philos Trans R Soc Lond B Biol Sci (2015) 1.40
Major histocompatibility complex independent clonal T cell anergy by direct interaction of Staphylococcus aureus enterotoxin B with the T cell antigen receptor. J Exp Med (1992) 1.37
Tolerogenicity of resting and activated B cells. J Exp Med (1994) 1.25
Peripheral tolerance to alloantigen results from altered regulation of the interleukin 2 pathway. J Exp Med (1991) 1.23
Intrinsic B-cell hyporesponsiveness accounts for self-tolerance in lysozyme/anti-lysozyme double-transgenic mice. Proc Natl Acad Sci U S A (1990) 1.17
Self-reactive T cells can escape clonal deletion in T-cell receptor V beta 8.1 transgenic mice. Proc Natl Acad Sci U S A (1990) 1.14
Tolerance of CD8+ T cells developing in parent-->F1 chimeras prepared with supralethal irradiation: step-wise induction of tolerance in the intrathymic and extrathymic environments. J Exp Med (1993) 1.03
Anti-CD4 mediates clonal anergy during transplantation tolerance induction. J Exp Med (1991) 1.03
Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival. J Exp Med (1994) 1.02
Peripheral tolerance in mice expressing a liver-specific class I molecule: inactivation/deletion of a T-cell subpopulation. Proc Natl Acad Sci U S A (1990) 1.02
Intrathymic clonal deletion of V beta 6+ T cells in cyclophosphamide-induced tolerance to H-2-compatible, Mls-disparate antigens. J Exp Med (1990) 1.01
Reshaping a therapeutic CD4 antibody. Proc Natl Acad Sci U S A (1991) 0.98
T cells augment monocyte and neutrophil function in host resistance against oropharyngeal candidiasis. Infect Immun (2001) 0.97
Harnessing FOXP3+ regulatory T cells for transplantation tolerance. J Clin Invest (2014) 0.95
Tolerance: an overview and perspectives. Nat Rev Nephrol (2010) 0.95
Extended repertoire of permissible peptide ligands for HLA-B*2702. Protein Sci (1996) 0.93
Regulation and privilege in transplantation tolerance. J Clin Immunol (2008) 0.93
Modulation of IL-17 and Foxp3 expression in the prevention of autoimmune arthritis in mice. PLoS One (2010) 0.92
Production of erythrocyte autoantibodies in NZB mice is inhibited by CD4 antibodies. Clin Exp Immunol (1994) 0.92
Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade. Hum Gene Ther (2015) 0.90
Boosting regulatory T cell function by CD4 stimulation enters the clinic. Front Immunol (2012) 0.87
Inhibition of allograft rejection by anti-T-cell receptor-alpha beta monoclonal antibodies preserving resistance to bacterial infection. Immunology (1994) 0.87
Selective anergy of V beta 8+ T cells in human immunodeficiency virus-infected individuals. J Exp Med (1994) 0.87
Regulatory cells and transplantation tolerance. Cold Spring Harb Perspect Med (2013) 0.86
Direct evidence for clonal destruction of allo-reactive T cells in the mice treated with cyclophosphamide after allo-priming. Immunology (1993) 0.85
A comparative study of T-cell receptor V beta usage in non-obese diabetic (NOD) and I-E transgenic NOD mice. Immunology (1993) 0.84
Murine Models of Transplantation Tolerance through Mixed Chimerism: Advances and Roadblocks. Clin Exp Immunol (2017) 0.83
Repeated Injections of IL-2 Break Renal Allograft Tolerance Induced via Mixed Hematopoietic Chimerism in Monkeys. Am J Transplant (2015) 0.82
Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection. J Transl Med (2009) 0.82
T cell tolerance induced by therapeutic antibodies. Philos Trans R Soc Lond B Biol Sci (2005) 0.81
Short-term administration of anti-L3T4 MoAb prevents diabetes in NOD mice. Clin Exp Immunol (1993) 0.81
Innate and adaptive immune responses are tolerized in chimeras prepared with nonmyeloablative conditioning. Transplantation (2012) 0.80
Experimental melanin-induced uveitis in the Fischer 344 rat is inhibited by anti-CD4 monoclonal antibody, but not by mannose-6-phosphate. Clin Exp Immunol (1999) 0.80
Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease. Clin Exp Immunol (1997) 0.80
Induction of Pancreatic Islet Graft Acceptance: The Role of Antigen Presenting Cells. Transplant Sci (1992) 0.78
Importance of intrathymic mixed chimerism for the maintenance of skin allograft tolerance across fully allogeneic antigens in mice. Immunology (1999) 0.77
CD8 blockade promotes the expansion of antigen-specific CD4+ FOXP3+ regulatory T cells in vivo. Int Immunopharmacol (2006) 0.76
T-cell receptor V beta repertoire of L3T4+ regulatory T cells in anti-L3T4 antibody-induced tolerant NOD mice. Immunology (1994) 0.75
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer (1977) 53.23
Actively acquired tolerance of foreign cells. Nature (1953) 19.82
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature (1985) 9.62
Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature (1988) 9.17
Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med (1987) 5.48
Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature (1984) 4.26
Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: long-term survival of allogeneic bone marrow and skin grafts. J Exp Med (1977) 3.48
Monoclonal antibodies against rat immunoglobulin kappa chains. Hybridoma (1982) 3.36
Deletion of self-reactive thymocytes occurs at a CD4+8+ precursor stage. Nature (1988) 2.84
Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature (1986) 2.25
In a fully H-2 incompatible chimera, T cells of donor origin can respond to minor histocompatibility antigens in association with either donor or host H-2 type. J Exp Med (1978) 1.79
Evidence from in vitro studies that tolerance to self antigens is MHC-restricted. Nature (1984) 1.54
Self tolerance is H-2-restricted. Nature (1984) 1.47
Role of the H-2 complex in the induction of T cell tolerance to self minor histocompatibility antigens. J Exp Med (1983) 1.42
Intrathymic elimination of Mlsa-reactive (V beta 6+) cells during neonatal tolerance induction to Mlsa-encoded antigens. J Exp Med (1988) 1.34
CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. Eur J Immunol (1987) 1.31
Renal allograft tolerance induced with ATG and donor bone marrow in outbred rhesus monkeys. Transplantation (1983) 1.19
T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation. Transplantation (1988) 1.18
Use of homozygous allogeneic bone marrow for induction of tolerance with antilymphocyte serum: dose and timing. Transplant Proc (1971) 1.16
Cellular factors. Immunologic tolerance: irradiation and bone marrow transplantation in induction of canine allogeneic unresponsiveness. Transplant Proc (1977) 1.07
Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4+ cells. J Immunol (1988) 0.99
Immunohistological screening in the selection of monoclonal antibodies: the use of isotype-specific antiglobulins. J Immunol Methods (1984) 0.95
Mechanisms of monoclonal antibody-facilitated tolerance induction: a possible role for the CD4 (L3T4) and CD11a (LFA-1) molecules in self-non-self discrimination. Eur J Immunol (1988) 0.95
Antibody-facilitated chimeras. Stem cell allotransplantation using antihost major histocompatibility complex monoclonal antibodies instead of lethal irradiation for host conditioning. Transplantation (1984) 0.94
Drug-induced tolerance to allografts in mice. IX. Establishment of complete chimerism by allogeneic spleen cell transplantation from donors made tolerant to H-2-identical recipients. Transplantation (1986) 0.92
Mechanisms of marrow graft rejection in murine model systems. Transplant Proc (1987) 0.88
Autoimmunity to Thy-1. Eur J Immunol (1986) 0.88
Proteolysis of rat IgG subclasses by Staphylococcus aureus V8 proteinase. Biochim Biophys Acta (1983) 0.83
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature (1985) 9.62
"Infectious" transplantation tolerance. Science (1993) 4.98
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol (2001) 4.97
Reshaping human antibodies for therapy. Nature (1988) 4.82
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med (1989) 4.19
Impaired resistance to Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+ and Lyt-2+ T cells. Infect Immun (1987) 3.87
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med (1987) 3.82
Different roles for L3T4+ and Lyt 2+ T cell subsets in the control of an acute herpes simplex virus infection of the skin and nervous system. J Gen Virol (1987) 3.16
Functional analysis of T lymphocyte subsets in antiviral host defense. J Immunol (1987) 3.11
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology (1990) 2.77
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia (2010) 2.65
Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet (1988) 2.51
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol (1999) 2.28
Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet (1998) 2.26
Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature (1986) 2.25
Allogeneic hematopoietic stem cell transplantation and norovirus gastroenteritis: a previously unrecognized cause of morbidity. Clin Infect Dis (2009) 2.04
IL-10 gene expression is controlled by the transcription factors Sp1 and Sp3. J Immunol (2000) 2.04
Unexpected mobilisation of lead during cisplatin chemotherapy. Lancet (1986) 1.95
Letter: T cell-dependent mediator in the immune response. Nature (1973) 1.94
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood (2000) 1.93
Regulating the immune response to transplants. a role for CD4+ regulatory cells? Immunity (2001) 1.90
The effect on the growth of BP8 ascites tumour in C3H-C57 or C3H mice of "lymphocyte preparations" from C57 mice injected with BP8 cells and Freund's adjuvant. Br J Cancer (1967) 1.88
Limiting dilution analysis of helper T-cell function. Immunology (1975) 1.82
Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood (1983) 1.80
Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest (1991) 1.79
Induction of tolerance in peripheral T cells with monoclonal antibodies. Eur J Immunol (1990) 1.79
Monocytic origin of foam cells in human atherosclerotic plaques. Atherosclerosis (1984) 1.78
The CAMPATH-1 antigen (CDw52). Tissue Antigens (1990) 1.78
Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Immunol Rev (1996) 1.77
Apolipoprotein E genes in Lewy body and Parkinson's disease. Lancet (1994) 1.77
T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease. Bone Marrow Transplant (1994) 1.76
Mechanisms of protection induced by attenuated simian immunodeficiency virus. II. Lymphocyte depletion does not abrogate protection. AIDS Res Hum Retroviruses (1998) 1.73
Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet (1992) 1.72
Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet (1999) 1.69
Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation (1999) 1.67
Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. Arthritis Rheum (2001) 1.67
Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. QJM (1996) 1.66
T cell-dependent mediator in the immune response. II. Physical and biological properties. Immunology (1974) 1.65
The influence of the major histocompatibility complex on the function of T-helper cells in antibody formation. Immunol Rev (1978) 1.64
Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med (1988) 1.63
Low molecular weight RNA species from chromatin. Biochemistry (1975) 1.62
Posttranscriptional regulation of IL-10 gene expression through sequences in the 3'-untranslated region. J Immunol (2000) 1.60
Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet (1994) 1.59
In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science (1995) 1.56
Cutting edge: anti-CD154 therapeutic antibodies induce infectious transplantation tolerance. J Immunol (2000) 1.55
Induction of tolerance by monoclonal antibody therapy. Nature (1986) 1.53
Cooperation across the histocompatibility barrier. Nature (1975) 1.51
CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression. J Immunol (1999) 1.50
Conditions determining the generation and expression of T helper cells. Immunol Rev (1977) 1.49
Skin allograft rejection by L3/T4+ and Lyt-2+ T cell subsets. Transplantation (1986) 1.49
Antigen-non-specific T-cell factor in B-cell activation. Origin, biological properties and failure to show a relationship to H-2. Immunology (1976) 1.49
A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer. Leukemia (2007) 1.47
Self tolerance is H-2-restricted. Nature (1984) 1.47
Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J (1993) 1.46
T cell suppression in transplantation tolerance through linked recognition. J Immunol (1996) 1.45
The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol (1993) 1.44
Regulation of IL-18 (IFN-gamma-inducing factor) gene expression. J Immunol (1997) 1.44
Radiotherapy-based conditioning is effective immunosuppression for patients undergoing transplantation with T-cell depleted stem cell grafts for severe aplasia. Cytotherapy (2004) 1.42
Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain (1996) 1.40
Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet (1993) 1.40
The role of CD4+ T-cell subsets in determining transplantation rejection or tolerance. Immunol Rev (2001) 1.40
Infectious tolerance. Curr Opin Immunol (1998) 1.39
T cell-dependent mediator in the immune response. III. The role of non-specific factor (NSF) in the in vitro immune response. Immunology (1975) 1.39
Use of Ceprate CD34-positive selection system for depletion of T cells in allogeneic transplantation. Bone Marrow Transplant (1997) 1.39
Amplification of natural regulatory immune mechanisms for transplantation tolerance. Transplantation (1996) 1.39
The induction of skin graft tolerance in major histocompatibility complex-mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies. Eur J Immunol (1990) 1.39
Regulation of CD40 function by its isoforms generated through alternative splicing. Proc Natl Acad Sci U S A (2001) 1.38
A rapid solid-phase enzyme-linked binding assay for screening monoclonal antibodies to cell surface antigens. J Immunol Methods (1981) 1.38
Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J Immunol (1985) 1.37
Identification of macrophages and smooth muscle cells in human atherosclerosis using monoclonal antibodies. J Pathol (1985) 1.34
Do L3T4+ T cells act as effector cells in protection against influenza virus infection. Immunology (1987) 1.33
Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest (1996) 1.33
Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med (1986) 1.33
Monoclonal-antibody therapy in systemic vasculitis. N Engl J Med (1990) 1.32
Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet (1984) 1.31
CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. Eur J Immunol (1987) 1.31
Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res (1995) 1.30
How do monoclonal antibodies induce tolerance? A role for infectious tolerance? Annu Rev Immunol (1998) 1.29
Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies. Immunol Rev (1992) 1.27
A role for CD4+ but not CD8+ T cells in immunity to Schistosoma mansoni induced by 20 krad-irradiated and Ro 11-3128-terminated infections. Immunology (1989) 1.27
A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer (1989) 1.27
Biology-inspired synthesis of compound libraries. Cell Mol Life Sci (2008) 1.26
Rejection of H-Y disparate skin grafts by monospecific CD4+ Th1 and Th2 cells: no requirement for CD8+ T cells or B cells. J Immunol (1998) 1.26
The immunogenicity of chimeric antibodies. J Exp Med (1989) 1.25
Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood (1989) 1.25
Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol (1991) 1.25
Rhabdomyosarcoma of the nose and paranasal sinuses in adults and children. Otolaryngol Head Neck Surg (1995) 1.24
S-Acylation and plasma membrane targeting of the farnesylated carboxyl-terminal peptide of N-ras in mammalian fibroblasts. Biochemistry (1997) 1.22
Benign methylmalonic aciduria. N Engl J Med (1984) 1.22
Tolerance to rat monoclonal antibodies. Implications for serotherapy. J Exp Med (1986) 1.21
Removal of T cells from bone marrow for transplantation. Comparison of rat monoclonal anti-lymphocyte antibodies of different isotypes. Mol Biol Med (1983) 1.21
Linked suppression of skin graft rejection can operate through indirect recognition. J Immunol (1998) 1.20
Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. The depletion of T cell subsets in vitro and in vivo. Transplantation (1986) 1.20